Imatinib Completed Phase 1 / 2 Trials for Recurrent Melanoma / Stage III Melanoma / Stage IV Melanoma / Unspecified Adult Solid Tumor, Protocol Specific Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00253565Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00084513Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer